Two year clinical and echocardiographic outcomes from the PARTNER 3 low risk randomized trial

29 Jun 2020

issue21_website images_CU1_Study2


  • Among low-risk patients with aortic stenosis, TAVR was superior to SAVR in preventing death, stroke, or rehospitalization at 1 year and was sustained to 2 years
  • TAVR was also associated with a lower incidence of stroke and atrial fibrillation, and a shorter hospital length of stay compared with SAVR
  • TAVR was associated with a larger improvement in quality of life compared with SAVR
  • There was a numerical increase in the need for new permanent pacemaker within 30 days in the TAVR group (6.5% with TAVR vs. 4.0% with SAVR); however, this difference was not statistically significant
  • Mild paravalvular aortic regurgitation occurred at a higher incidence in the TAVR group. The incidence of moderate to severe aortic regurgitation was rare (<1%) and similar between treatment groups
  • As compared to TAVR, SAVR was associated with an increased incidence of valve thrombosis (VARC-2 definition) and increased mean transvalvular gradient at 2 years

“This is a landmark trial which will expand the penetration of TAVR in the treatment of aortic stenosis. Planned future researches will examine the long-term outcomes and valve durability”

Get access to our exclusive articles.